Company Category: Research Technology

Scienta is a techbio company founded in 2021, dedicated to transforming drug development in immunology and inflammation. By combining proprietary disease-specific data assets with next-generation foundation model AI, Scienta bridges the translational gap that has long made I&I drug development among the most costly and failure-prone in the pharmaceutical industry. Despite decades of research and significant investment, the majority of immunology drug candidates still fail in clinical trials, largely due to poor translation from animal models to human patients. Phase II failure rates in I&I remain stubbornly high, driven by an inability to reliably predict which patients will respond to a given therapy before a costly trial begins. Scienta was built to address this challenge at its root. At the core of Scienta’s platform is EVA, the first cross-species, multimodal foundation model dedicated exclusively to immunology and inflammation. EVA learns from ImmunAtlas, Scienta’s proprietary curated database aggregating over 600,000 patient and biosample profiles across more than 30 immune-mediated diseases, integrating clinical, transcriptomic, histological, and proteomic data from 70+ tissues and more than 3 billion biological data points. EVA operates across the full drug development pipeline. At the discovery stage, it enables zero-shot target efficacy and gene function prediction to identify and prioritize the most promising therapeutic mechanisms. In preclinical development, it models cross-species and cross-disease molecular perturbations to anticipate how a drug candidate will impact immune networks in humans, going beyond what animal models alone can reveal. At the clinical stage, it supports patient stratification, treatment response prediction, and disease activity forecasting to identify the right patients for the right therapies before trials begin. In independent benchmarking across 39 immune-specific tasks spanning the drug development pipeline, EVA achieved state-of-the-art results, outperforming both generalist biological foundation models and conventional baselines. These results have been validated through peer-reviewed publications and presentations at leading biomedical and AI conferences. Scienta’s technology has been validated in concrete biopharma partnerships, with applications spanning dermatology, gastroenterology, rheumatology and neurology. Unlike generalist AI platforms or single-cell-focused tools, Scienta combines two capabilities rarely found together: high translational capability bridging preclinical to clinical development, and disease-specific explainability. Models are built to be interrogated, providing mechanistic interpretability that helps scientists understand why a prediction is made. This positions Scienta uniquely at the intersection of molecular precision and systemic, patient-level modeling. Scienta was co-founded by Camille Bouget (CEO, PharmD, previous experience across Sanofi, Sandoz, and Galapagos), Vincent Bouget (CSO, CentraleSupélec / MSc Biomedical Sciences), and Julien Duquesne (CTO, CentraleSupélec / MSc MVA, ENS Paris-Saclay). The company has raised 6.5 million euros in total funding, including support from the European Innovation Council’s EIC Accelerator, the EU’s flagship program for breakthrough deep-tech innovations.